Draig Therapeutics, a UK-based biotech emerging from stealth, secured a $140 million Series A funding round to advance its neuropsychiatry pipeline. The financing, backed notably by Sanofi's venture arm, supports a lead molecule poised for Phase 2 trials targeting major depressive disorder. This substantial capital injection highlights growing investor confidence in novel therapies addressing unmet needs in mental health.